These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 24218606

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
    Li F, Ravetch JV.
    Science; 2011 Aug 19; 333(6045):1030-4. PubMed ID: 21852502
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
    White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ.
    Cancer Immunol Immunother; 2013 May 19; 62(5):941-8. PubMed ID: 23543215
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
    Richman LP, Vonderheide RH.
    Cancer Immunol Res; 2014 Jan 19; 2(1):19-26. PubMed ID: 24416732
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
    Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A.
    Cancer Cell; 2011 Jan 18; 19(1):101-13. PubMed ID: 21251615
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
    Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV.
    Cancer Cell; 2016 Jun 13; 29(6):820-831. PubMed ID: 27265505
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
    White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.
    J Immunol; 2011 Aug 15; 187(4):1754-63. PubMed ID: 21742972
    [Abstract] [Full Text] [Related]

  • 19. Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF).
    Medler J, Wajant H.
    Methods Mol Biol; 2021 Aug 15; 2248():81-90. PubMed ID: 33185869
    [Abstract] [Full Text] [Related]

  • 20. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor.
    Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, Chen H, Lee SH, Leung I, Bonzon C, Desjarlais JR, Stohl W, Szymkowski DE.
    Arthritis Rheumatol; 2014 May 15; 66(5):1153-64. PubMed ID: 24782179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.